Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards

BACKGROUND: Up to 83% of patients with SLE stop taking hydroxychloroquine (HCQ) within the first year due to knowledge gaps regarding the survival benefits of HCQ versus inflated fears of rare toxicity. Thus, there is a need for a shared decision-making tool that highlights HCQ’s significant benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Shivani, Ferguson, Sancia, Chewning, Betty, Gomez, Shelby, Keevil, Jon, Bartels, Christie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Epidemiology and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387621/
https://www.ncbi.nlm.nih.gov/pubmed/37500292
http://dx.doi.org/10.1136/lupus-2023-000935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387621/
https://www.ncbi.nlm.nih.gov/pubmed/37500292
http://dx.doi.org/10.1136/lupus-2023-000935

Ejemplares similares